# CIOMS Working Group XIV Releases Validation Standards for > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cioms-working-group-xiv-releases-validation-standards-for-ai-in-pharmacovigilance/ > **Published:** 2026-08-28T07:12:06-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:41:54-04:00 > **Clinical Summary:** Learn about CIOMS Working Group XIV's new validation standards for AI in pharmacovigilance, enhancing cannabis safety monitoring. --- ✦ New CED Clinical Relevance #77 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. PolicyResearchHempCBDNeurologySafetyPain Why This Matters This article matters for clinicians and their patients as it introduces validation standards for Artificial Intelligence (AI) in pharmacovigilance, which could potentially improve the safety monitoring of cannabis-based products. The development of these standards may lead to more effective and efficient identification of adverse events related to cannabinoids, thereby enhancing [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/). Additionally, the Rare Cannabinoid Company’s educational guide on the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) and hemp compounds provides valuable information for clinicians to better understand and utilize these substances in their practice, ultimately benefiting their patients. Clinical Summary The CIOMS Working Group XIV has released validation standards for Artificial Intelligence in pharmacovigilance, which could potentially impact the safety monitoring and assessment of cannabis-based medications in [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/). This development may lead to improved [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) by enhancing the detection and management of adverse events associated with these compounds. The practical takeaway is that clinicians should be aware of these standards as they may influence the quality, access, and safety of cannabis medicines in the future. Dr. Caplan’s Take “As a seasoned family physician specializing in [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/), the CIOMS Working Group XIV’s validation standards for AI in pharmacovigilance are a significant stride towards ensuring [patient safety](https://cedclinic.com/indiana-marijuana-legalization-policy-addressing-lagging-reform/) and efficacy in our rapidly evolving field. The Rare Cannabinoid Company’s educational guide on the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) and hemp compounds is commendable, though it’s important to acknowledge that industry reports, while informative, should be corroborated with peer-reviewed research before being fully integrated into [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/).” Clinical Perspective 🔬 In the realm of healthcare, the recent release of validation standards for Artificial Intelligence (AI) in pharmacovigilance by CIOMS Working Group XIV signifies a significant step towards integrating AI in drug safety monitoring. This development, coupled with Rare Cannabinoid Company’s educational guide on the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) and hemp compounds, underscores the growing interest in cannabis-derived therapies. However, it’s crucial to acknowledge the complexity of these substances, their interactions with other medications, and potential confounders such as individual patient variability and legal regulations. As healthcare providers, we must stay informed about emerging research and guidelines to ensure safe and effective use of cannabis-derived products in [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/). Practically, this means continued education on the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/), understanding the potential benefits and risks associated with various hemp compounds, 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20CIOMS%20Working%20Group%20XIV%20Releases%20Validation%20Standards%20for%20AI%20in%20Pharmacovigilance%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D75028)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D75028)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20CIOMS%20Working%20Group%20XIV%20Releases%20Validation%20Standards%20for%20AI%20in%20Pharmacovigilance%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D75028)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://www.geneonline.com/cioms-working-group-xiv-releases-validation-standards-for-ai-in-pharmacovigilance/](https://www.geneonline.com/cioms-working-group-xiv-releases-validation-standards-for-ai-in-pharmacovigilance/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).